Principal Global Investors, a Delaware-incorporated investment adviser, filed an amended beneficial ownership statement with the SEC on October 28, 2026, disclosing a 4.7% stake in Collegium Pharmaceutical, Inc. as of September 30, 2026.

Key Highlights

  • Beneficial ownership total: Principal Global Investors reported aggregate beneficial ownership of 1,514,310 shares of Collegium Pharmaceutical common stock.
  • Percent of class: The 1,514,310 shares represent 4.7% of Collegium Pharmaceutical's outstanding common stock.
  • Voting and dispositive power: Principal Global Investors reported 0 shares with sole voting or sole dispositive power, and 1,514,310 shares with shared voting and shared dispositive power.
  • Event date: The event requiring this filing occurred on September 30, 2026.
  • Filing type: This is Amendment No. 1 to a prior beneficial ownership statement, signed by J. Markham Penrod, Chief Compliance Officer - North America, Principal Asset Management.
  • Ordinary course certification: The filing certifies that the securities "were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer."

Principal Global Investors Discloses Amended Ownership Position in Collegium Pharmaceutical

Principal Global Investors, organized in Delaware and operating as a registered investment adviser, submitted Amendment No. 1 to its beneficial ownership statement covering shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL), a specialty pharmaceutical company headquartered at 100 Technology Center Drive, Stoughton, Massachusetts 02072. The filing was triggered by an event dated September 30, 2026, and was signed and dated October 28, 2026.

According to the filing, Principal Global Investors holds 1,514,310 shares of Collegium Pharmaceutical's common stock, par value $0.001 per share (CUSIP 19459J104), representing 4.7% of the class. All 1,514,310 shares are reported under shared voting power and shared dispositive power, with no shares attributed to sole voting or sole dispositive power. The filing designates Principal Global Investors as an investment adviser under the applicable reporting classification, with its principal business office located at 711 High Street, Des Moines, Iowa 50392-0300.

The amendment falls under Item 5 of the filing, which addresses ownership of 5 percent or less of a class. Items 6 through 9 of the statement - covering ownership on behalf of another person, subsidiary identification, group membership, and group dissolution - were each reported as "Not Applicable." J. Markham Penrod, identified as Chief Compliance Officer - North America of Principal Asset Management, signed the certification accompanying the disclosure.

What Was Disclosed

Principal Global Investors filed an amended statement reporting beneficial ownership of 1,514,310 shares, or 4.7%, of Collegium Pharmaceutical's common stock as of September 30, 2026, with all shares held under shared voting and shared dispositive power.